Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902503 | 0.83 | GAA (0.58) | GAAHTTEPHX2MAPK1TP53 | |
| SCHEMBL3916064 | 0.80 | GAA (0.50) | GAAHTTEPHX2MAPK1TP53 | |
| SCHEMBL2796863 | 0.79 | L3MBTL1 (0.56) | SMN1; SMN2L3MBTL1POLB | |
| SCHEMBL192886 | 0.78 | L3MBTL1 (0.59) | GAAL3MBTL1MAPTPOLB | |
| SCHEMBL6240853 | 0.78 | KMT2A (0.49) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL24032218 | 0.76 | L3MBTL1 (0.41) | EPHX2L3MBTL1ALDH1A1MAPTNR1H4 | |
| SCHEMBL31488233 | 0.76 | MAPT (0.58) | GAAHTTL3MBTL1GPR88MAPT | |
| SCHEMBL4935297 | 0.75 | EPHX2 (0.58) | GAAHTTEPHX2MAPK1TP53 | |
| SCHEMBL24032219 | 0.75 | L3MBTL1 (0.40) | L3MBTL1TSHR | |
| SCHEMBL22823950 | 0.74 | GAA (0.58) | GAAHTTEPHX2MAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476759-B2 | e.g. 4-Amino-3-(4'-cyano-1,1'-biphenyl-4-yl)-4-oxobutanoic acid; antiinflammatory , anticarcinogenic, antiasthmatic agent; autoimmune disorder; osteoarthritis, rubella, Alzheimer's, Parkinson's diseases, epilepsy, osteoporosis | GLAXO GROUP LIMITED (GB) | 2009-01-13 | — | — | US | disclosed |
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP9, MMP24 | GAA 1135/4885HTT 4566/4885EPHX2 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.